UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the Month of October
Commission File Number 000-50994
BioProgress PLC
(Translation of registrant’s name into English)
15-17 Cambridge Science Park
Milton Road, Cambridge CB4 0FQ
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F X Form 40-F
Indicate by check mark whether registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):N/A
.
26 October 2006
BioProgress plc ("BioProgress" or the "Company")
Share Price Movement
The Company has noted the recent move in its share price and wishes to announce
that it is in advanced discussions for the acquisition of assets relating to a
US business for a consideration of up to US$8 million to be satisfied as to 50
per cent. cash and 50 per cent. shares. In addition, the Company, advised by
Bridgewell Limited, is contemplating a cash placing pursuant to the
authorisation of the Board under Section 95 of the Companies Act.
A further announcement will be made in due course.
Enquires:
Bridgewell Limited
Chris Madderson +44 (0) 20 7003 3153
BioProgress plc
Richard Trevillion +44 (0) 20 7098 9881
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.